Navigating Stage-Appropriate Quality System Design

By |2024-02-06T14:06:00-05:0006/29/2023|

Navigating Stage-Appropriate Quality System Design Originally Published as a MassBio Guest Blog Our emerging biotech and biopharma clients often request support from our skilled consultants and practitioners to develop a “Stage-Appropriate cGMP Quality System." However, we find that they are often not fully aware of what “stage-appropriate” means or what it looks [...]

What Commercial Companies Need to Know about S&OP

By |2024-02-06T14:12:14-05:0011/09/2022|

What Commercial Companies Need to Know about S&OP Sales and Operations Planning (S&OP) is an iterative planning process. It ensures cross-functional alignment on sales forecast and performance, as well as manufacturing forecast and performance. It also provides visibility into forecasted demand and an accurate view of volumes for inventory and production. With this [...]

Info Sheet: Extending Your Quality Capabilities

By |2024-02-06T15:00:21-05:0008/18/2022|

Extending Your Quality Capabilities Info Sheet Download PDF Focusing on patients and improved outcomes in a rapidly evolving environment requires maintaining appropriate controls to ensure quality and compliance from early in the lifecycle. A well-designed and stage-appropriate Quality Management System (QMS) is essential to facilitate the development and commercialization of these advanced [...]

Transitioning to Computer Software Assurance from Computer Systems Validation

By |2023-03-16T10:27:15-04:0003/29/2022|

Transitioning to Computer Software Assurance from Computer Systems Validation Life science companies need to verify that GxP computer and software systems accurately support their intended business processes. The traditional approach for meeting this requirement is computer system validation (CSV). CSV emerged decades ago when computer systems were less reliable, and software was [...]

Event Recap: Building High-Touch Patient Supply Chains

By |2022-11-14T11:51:17-05:0003/18/2022|

Event Recap: Building High-Touch Patient Supply Chains Patient Outcomes: A Shift in Industry Focus The healthcare industry is increasing use of patient outcomes as a measure of quality and value. This drives biopharmaceutical companies to focus on patients in their commercial operations, technical operations, and supply chain. It was first prioritized [...]

Advanced Planning: Developing Supply Risk Mitigation Strategies

By |2024-02-06T10:05:52-05:0002/09/2022|

Advanced Planning: Developing Supply Risk Mitigation Strategies PDF Version Converge conducts a Manufacturing Supplier Risk Assessment and uses the results to build a Supplier Risk Management Plan. A commercial biopharmaceutical company was preparing for their second product launch when senior leadership acknowledged the need to prioritize the supply chain and manufacturing mandates [...]

5 Unique Logistics Challenges for Specialty Pharmaceuticals

By |2024-02-06T11:12:39-05:0007/28/2021|

5 Unique Logistics Challenges for Specialty Pharmaceuticals Many of our clients are innovator companies developing novel treatments that are often complex and extremely high value. As a result, they face similar supply chain challenges in preparing for commercialization. Often, these specialty products are also orphan and rare disease treatments, as well as extremely [...]

Thinking Differently about Safety Stock

By |2021-04-13T11:37:36-04:0004/13/2021|

Inventory comes in many shapes and sizes, quite literally, but for life sciences one thing is certain: effectively managing inventory is a make-or-break moment for delivering patient-centric care. I have seen this value potential play out while working with dozens of emerging companies to build efficient inventory management strategies. Many senior leaders underestimate how [...]

Ensuring the Path to Compliant Analytical Methods

By |2024-02-06T10:27:14-05:0011/06/2020|

Ensuring the Path to Compliant Analytical Methods PDF Version A gene therapy company spent over a decade developing their first-generation product, partnering for many early development capabilities. Then when the product was moving into the final stage clinical development, they bought out the rights and now owned 100% of the molecule. However, [...]

Go to Top